Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 12/20 | 0.44 |
| ▸ | CTSS | P25774 | 10/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19373028 | 1.00 | CTSK (0.44) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL6624042 | 0.85 | CA1 (0.43) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL18681498 | 0.85 | CA1 (0.43) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL20750960 | 0.85 | CA1 (0.43) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL23736310 | 0.80 | CA1 (0.40) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL1106536 | 0.78 | CA1 (0.49) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL4217171 | 0.78 | CA1 (0.49) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL29610548 | 0.78 | CA1 (0.49) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL24301038 | 0.78 | CTSK (0.42) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL20029331 | 0.78 | CTSK (0.46) | CTSKCTSSCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140895-B1 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-03-24 | — | — | EP | claimed |
| US-20230348405-A1 | PSMA-TARGETING COMPOUNDS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSTY | 2023-11-02 | — | — | US | disclosed |
| US-11661402-B2 | PSMA-targeting compounds and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-05-30 | — | — | US | disclosed |
| US-9776977-B2 | PSMA-targeting compounds and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-10-03 | — | — | US | disclosed |
| US-9776977-B2 | PSMA-targeting compounds and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-10-03 | — | — | US | disclosed |
| EP-3222617-A1 | PSMA-TARGETING COMPOUNDS AND USES THEREOF | The Johns Hopkins University (US) | 2017-09-27 | — | — | EP | disclosed |
| EP-2408755-B1 | Urea-based peptide compounds useful for detecting inter alia prostate cancer | UNIV JOHNS HOPKINS (US) | 2017-05-03 | — | — | EP | disclosed |
| US-9056841-B2 | PSMA-targeting compounds and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-06-16 | — | — | US | disclosed |
| US-9056841-B2 | PSMA-targeting compounds and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-06-16 | — | — | US | disclosed |
| US-20150104387-A1 | PSMA-TARGETING COMPOUNDS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-04-16 | — | — | US | disclosed |
| US-20150104387-A1 | PSMA-TARGETING COMPOUNDS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-04-16 | — | — | US | disclosed |
| US-20120009121-A1 | PSMA-TARGETING COMPOUNDS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-01-12 | — | — | US | disclosed |
| WO-2010108125-A2 | PSMA-TARGETING COMPOUNDS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009121-A1 | PSMA-TARGETING COMPOUNDS AND USES THEREOF | FOLH1, KLK3, PSMA2 | CTSK 579/4885CTSS 592/4885CA1 474/4885 |
| US-20230348405-A1 | PSMA-TARGETING COMPOUNDS AND USES THEREOF | KLK3, FOLH1, SPR | CTSK 535/4885CTSS 504/4885CA1 108/4885 |
| US-20150104387-A1 | PSMA-TARGETING COMPOUNDS AND USES THEREOF | FOLH1, KLK3, PSMA2 | CTSK 579/4885CTSS 592/4885CA1 474/4885 |
| US-11661402-B2 | PSMA-targeting compounds and uses thereof | KLK3, FOLH1, SPR | CTSK 535/4885CTSS 504/4885CA1 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.